Fabio Arcidiacono: Five year survival and safety outcomes from the START-NEW-ERA non-randomized phase II trial #ESTRO24 #LCSM #radonc

PLATO ACT 4: Ph II RCT of 50.4 vs. 41.4 Gy for T1-2 (<4 cm) N0 anal SCC. No difference in 3-year local recurrence (primary endpoint) or OS, & better toxicity/QOL with dose-reduction. Should 41.4 Gy be a SOC option (ahead of Ph III DECREASE trial reporting)? #ESTRO25

Best #ESTRO2025 abstract for EMBRACE2 showing excellent locoregional control and significantly reduced morbidity compared to embrace 1 with tighter dose constraints with higher use of hybrid applicator ( new standard ) DrKamrava Scott Glaser Andrew Keller American Brachy

EMBRACE II: New standard of care for locally advanced cervical cancer! 📌 Advanced RT technology. 📌 Image-guided adaptive brachytherapy. 📌 Limited overall treatment time. 📌 Excellent disease control and overall survival. 📌 Low late severe morbidity. #ESTRO2025

PORTEC 4a results . High risk benefits from EBRT ( only 25% had LND) and low risk has small but non inferior difference in vaginal recurrence with VBT DrKamrava Andrew Keller

📢 STORM trial breaking results at #ESTRO25! 🧪 MDT vs ENRT+MDT for nodal oligorecurrent PCa. 🧬 ENRT+MDT: ✅ Superior bRFS (57% vs 41%, p=0.014) ✅ Superior pelvic control (lrRFS 85% vs 62%, p=0.006) ✅ Superior MFS (76% vs 63%, p=0.06) ❌ No increase in ≥G2 GU/GI toxicity

I’m excited to share that our publication of the first modern American case series for the treatment of Osteoarthritis (OA) with Low Dose Radiotherapy (LDRT) is now published and available online in the red journal. The American patient population differs significantly from

#ASCO25: In pts with 5–20 brain mets, Phase 3 trial shows SRS/SRT leads to significantly better QoL vs HA-WBRT (↓ symptoms & interference, p<0.001), with no OS difference (8.3 vs 8.5 mo). SRS/SRT should be new SoC in this setting. #radonc 🔗 meetings.asco.org/abstracts-pres…

❗️ CM577 CRT -> surgery -> non-pCR randomized to adjuvant nivolumab vs placebo Primary endpoint: DFS First OS results: mOS 51.7 vs 35.3 mo HR 0.85 (95.87% CI 0.70–1.04)

This paper is absolutely fantastic. It is essentially the Bible for NPC CTV delineation. Incredible contribution to the field! redjournal.org/article/S0360-…

New in #practicalRO: A Resident’s Guide to Evaluation of Prostate High Dose Rate Brachytherapy Treatment Plans: An American Brachytherapy Society Technical Report. #radonc tinyurl.com/prohathout

‼️ TAUTEM Phase 3 RCT T2-3bN0M0 rectal cancer -> chemoradiation and transanal excision vs TME DFS in both groups was 88.9%! Win for organ preservation and patients! jamanetwork.com/journals/jamas…

🧵1/ Big news in unresectable stage III NSCLC. The InTRist study is the first randomized trial comparing NAC vs. neoadjuvant chemoimmunotherapy (NAC-ICI) prior to definitive chemoradiotherapy (CRT). Early results are promising. Let’s dig in. 🔍 #LungCancer #RadOnc #ASCO25

In pts w well-controlled HIV & anal SCC, retifanlimab (PD-1 inhibitor) appears similarly efficacious w no increased toxicity (vs. pts w/o HIV), & did not negatively impact HIV control. Important results given recent approval of retifanlimab in M1 anal SCC. #ASCO25 OncoAlert

🔥❓Is Pre-op Chemoradiation the new SoC for locally advanced gallbladder cancer❓🔥 🚨POLCA-GB🚨 T3-4 or N+ GB cancer 🔍Gem-Cis +- CRT CRT Demonstrated: ✅⬆️OS, at median and with substantial separation at tail of curve (read: dcurability) ✅⬆️PFS ✅⬆️Objective response ✅No

Presented at #ASCO25: A 3-year structured exercise program after adjuvant chemotherapy for colon cancer improved disease-free and overall survival, physical functioning, and fitness, as compared with health education alone. Full CHALLENGE phase 3 trial results:

Game-changer at #ASCO25 🔥 Pre-plenary press release!! ATOMIC is the most important adjuvant study yet for MSI-H colon cancer—and it’s practice-changing. 🧬 Stage III dMMR colon cancer 🧪 Atezolizumab + mFOLFOX6 vs mFOLFOX6 alone 💥 3-yr DFS: 86.4% vs 76.6% ⚖️ HR 0.50 | p <

This is a major story from #ASCO25. Randomized phase 3 trial of time of day of immunotherapy infusion. Randomized to infusion before or after 3pm. Early infusion far superior: PFS 11.3 vs 5.7 HR 0.42, OS HR 0.45! Impactful, pragmatic, not costly. This should be a bigger story.

Bottom line from the #ctDNA analyses in CALLA study in #CervicalCancer (addition of durva to chemoradiation) 👀 Low ctDNA both at baseline and after completion of chemoXRT associated with better survival 🤔 ctDNA status was most significant prognostic factor #ASCO25 #gyncsm

❗️ B51 manuscript landed T1-3N1M0 -> ypN0 -> +/- RNI Primary endpoint: invasive breast cancer RFI HR 0.88 (0.60-1.28) pubmed.ncbi.nlm.nih.gov/40466065/